克羅格於2024年10月4日完成其專業藥房業務的出售，售價爲4.64億美元。此次出售使公司第三季度的總銷售額比去年同期減少了大約3.4億美元，預計未來年度銷售將減少約30億美元。KSP是一項低利潤業務，其出售提高了克羅格的毛利率以及以銷售爲比率的經營、一般和管理成本，對營業利潤沒有實質性影響。
以上內容來自Benzinga Earnings專欄，原文如下：
Sale of Kroger Specialty Pharmacy
Kroger closed the sale of its specialty pharmacy business on October 4, 2024, for $464 million. The sale reduced total company sales in the third quarter by approximately $340 million, compared to the same period last year, and annualized sales will be approximately $3 billion lower going forward. KSP was a low margin business. As a result, the sale of the business increased both Kroger's gross margin and operating, general and administrative costs as a rate of sales. It had no material effect on operating profit.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。